리가켐바이오
141080KOSDAQ자연과학 및 공학 연구개발업46.8 / 100
Reference Date: 2026-07-24
Company InformationBased on 2025 Annual Report
Business Overview
Ligacem Bio is a biopharmaceutical company specializing in next-generation ADC (Antibody-Drug Conjugate) technology through its proprietary platform 'ConjuALL', targeting unmet medical needs in oncology. The company has secured multiple technology transfer agreements with global pharmaceutical firms, including Fosun Pharma and Janssen, and reported revenue of approximately 10.54 billion KRW in 2024. It also operates a medical supply business, contributing to its diversified revenue streams.
Number of Employees
180people
Average Salary
157.1M KRW
Score Calculation Basis
Detailed Financial Score
2.8x industry avg (risky)
Well below industry avg
2.5x industry avg (risky)
Avg ▲140.6% (2-year basis)
Avg ▼167.5% (2-year basis)
Avg ROE -18.0% (improving, 3yr)
Detailed News Sentiment
- Negative[취재수첩] 안전장치 없는 우선주·CB 투자한 국민성장펀드
국민성장펀드의 우선주 및 CB 투자 논란으로 인해 리가켐바이오의 신뢰도 하락 우려.
- Positive외국인 2조원 사들여…코스피 7천선 다시 넘었다
외국인의 대규모 매수로 코스피가 7천선을 돌파하며 리가켐바이오를 포함한 관련 주식들에 긍정적 영향을 미쳤다.
- Neutral
Detailed Momentum
Near 52w low (6%, downtrend)
1m -33.36% (strong drop)
Volume decreasing
Detailed Disclosure
- Neutral[기재정정]주요사항보고서(전환사채권발행결정)2026-07-22
- Positive[기재정정]주요사항보고서(유상증자결정)2026-07-22
- Neutral[기재정정]주요사항보고서(전환사채권발행결정)2026-07-16
- Positive[기재정정]주요사항보고서(유상증자결정)2026-07-16
- Neutral투자판단관련주요경영사항 (LCB97 관련 마일스톤 기술료 수령)2026-07-09